bpc-157 pharmacokinetic half-life Frontiers Multifunctionality and Possible Medical Application

It binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at its receptor, c-Met

It completed Phase 2 trials in obesity [3] and type 2 diabetes [4] and moved into a Phase 3 program (TRIUMPH)

They are not typically associated with dependency or severe side effects, although minor issues such as nasal irritation or insomnia may occur

Besides, as indicated specifically in skin wound healing (Tkalcevic et al., 2007), BPC 157 half-life is long enough to exert a therapeutically stimulating effect on connective tissue growth (Tkalcevic et al., 2007)

Side Effects and Safety Like most peptides targeting appetite and metabolism, Cagrilintides side effects are largely gastrointestinal and dose-dependent